| Title |
Metreleptin: First Global Approval
|
|---|---|
| Published in |
Drugs, June 2013
|
| DOI | 10.1007/s40265-013-0074-7 |
| Pubmed ID | |
| Authors |
Ken Chou, Caroline M. Perry |
| Abstract |
Metreleptin is an analogue of the human hormone leptin being developed by Amylin Pharmaceuticals (a subsidiary of Bristol-Myers Squibb) for the subcutaneous treatment of metabolic disorders including lipodystrophy. The compound is expected to improve insulin sensitivity, hypertriglyceridaemia and hyperglycaemia in patients with lipodystrophy who are unresponsive to conventional treatment. Metreleptin has been approved in Japan as a leptin therapy for the treatment of lipodystrophy. Amylin has also completed a submission for regulatory approval to the US FDA for metreleptin in the treatment of diabetes mellitus and/or hypertriglyceridaemia in patients with rare forms of lipodystrophy. Clinical development of the drug is also underway in the USA for the treatment of type 1 diabetes. Amgen was previously assessing the use of metreleptin as a treatment for amenorrhoea; however, it appears that development in this indication has been discontinued. This article summarizes the milestones in the development of metreleptin leading to this first approval for lipodystrophy. |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 69 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 13% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Master | 7 | 10% |
| Student > Doctoral Student | 5 | 7% |
| Researcher | 5 | 7% |
| Other | 14 | 20% |
| Unknown | 22 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 26% |
| Biochemistry, Genetics and Molecular Biology | 9 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Agricultural and Biological Sciences | 3 | 4% |
| Chemistry | 3 | 4% |
| Other | 7 | 10% |
| Unknown | 25 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2024.
All research outputs
#2,435,108
of 23,269,984 outputs
Outputs from Drugs
#270
of 3,297 outputs
Outputs of similar age
#21,641
of 198,985 outputs
Outputs of similar age from Drugs
#1
of 32 outputs
Altmetric has tracked 23,269,984 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,297 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,985 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.